Astellas Pharma US, Inc.
Northbrook
Illinois
60062
United States
746 articles about Astellas Pharma US, Inc.
-
Medivation, Inc. and Astellas Pharma Inc. Announce Enzalutamide Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event
6/4/2012
-
AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) and Astellas Pharma Inc. Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
6/4/2012
-
Astellas Pharma Inc. and Drais Pharmaceuticals Partner to Develop Second Astellas Compound Through Seldar
6/4/2012
-
Medivation, Inc. and Astellas Pharma Inc. Announce Initiation of Expanded Access Program for Enzalutamide (formerly MDV3100) in the United States
5/30/2012
-
Astellas Pharma Inc./Medivation, Inc. File Prostate Cancer Drug in USA
5/22/2012
-
Medivation, Inc. and Astellas Pharma Inc. Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at American Society of Clinical Oncology Annual Meeting 2012
5/18/2012
-
Tolerability of Aveo/Astellas Pharma Inc. Kidney Cancer Drug Impresses
5/17/2012
-
MediGene AG Receives EUR 5 Million Milestone Payment From Astellas Pharma Inc.
5/7/2012
-
Drugmakers Astellas Pharma Inc. and Eli Lilly and Company Generate Alot of Buzz
4/12/2012
-
Astellas Pharma Inc. Wins FDA Panel Backing for Overactive Bladder Drug
4/6/2012
-
Astellas Pharma Inc. Overactive Bladder Drug Raises Blood Pressure Dangers, FDA Says
4/3/2012
-
Astellas Pharma Inc. and Vical Incorporated Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical
4/2/2012
-
Optimer Pharmaceuticals, Inc., Astellas Pharma Inc. Ink Pact Worth Up to $110 Million to Commercialize Fidaxomicin for Clostridium Difficile Infection in Japan
3/29/2012
-
Astellas Pharma Inc. Extends Deal to Sell Pfizer Inc.'s Lipitor in Japan
3/29/2012
-
AUA Foundation Announces Renewal of the Astellas Pharma Inc. Rising Stars in Urology Award Program
3/16/2012
-
Astellas Pharma Inc. and Medivation, Inc. Release: MDV3100 Extends Life by Nearly Five Months in Men with Advanced Prostate Cancer Post Chemotherapy 1
2/27/2012
-
Astellas Pharma Inc. Hires Senior Vice President of New Global Medical Affairs Organization
2/21/2012
-
National Comprehensive Cancer Network Collaborates with AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. on Innovative Cancer Research
2/17/2012
-
Astellas Pharma Inc. and Theravance, Inc. Announce Termination of License, Development and Commercialization Agreement for VIBATIV(R) (telavancin) for Injection
1/9/2012
-
Ambit Biosciences and Astellas Pharma Inc. Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Society of Hematology
12/13/2011